NPM1 Mutation clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
open to eligible people ages 18 years and up
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
at UC Irvine UCLA
Last updated: